BTIG Research Lowers MDxHealth (NASDAQ:MDXH) Price Target to $4.00

MDxHealth (NASDAQ:MDXH) had its price target cut by equities research analysts at BTIG Research from $7.00 to $4.00 in a report released on Thursday, Marketbeat Ratings reports. The brokerage presently has a “buy” rating on the stock. BTIG Research’s price objective points to a potential upside of 347.93% from the stock’s previous close.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of MDxHealth in a research note on Friday, March 27th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, MDxHealth presently has a consensus rating of “Moderate Buy” and an average price target of $4.63.

MDxHealth Trading Down 9.3%

MDXH opened at $0.89 on Thursday. The company has a market cap of $44.20 million, a price-to-earnings ratio of -1.37 and a beta of 1.60. The company’s 50 day moving average is $2.42 and its 200 day moving average is $3.23. MDxHealth has a 12-month low of $0.68 and a 12-month high of $5.33.

MDxHealth (NASDAQ:MDXH) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The business had revenue of $23.90 million during the quarter, compared to analysts’ expectations of $30.89 million. MDxHealth had a negative return on equity of 1,078.01% and a negative net margin of 29.90%. As a group, analysts predict that MDxHealth will post -0.41 EPS for the current fiscal year.

Institutional Investors Weigh In On MDxHealth

Several large investors have recently bought and sold shares of the business. Perkins Capital Management Inc. increased its position in MDxHealth by 7.1% in the first quarter. Perkins Capital Management Inc. now owns 1,476,441 shares of the company’s stock worth $3,396,000 after purchasing an additional 97,500 shares during the last quarter. Kennedy Capital Management LLC bought a new stake in MDxHealth in the third quarter worth $1,826,000. FreeGulliver LLC increased its position in MDxHealth by 25.7% in the fourth quarter. FreeGulliver LLC now owns 317,894 shares of the company’s stock worth $1,135,000 after purchasing an additional 65,000 shares during the last quarter. Renaissance Technologies LLC increased its position in MDxHealth by 21.8% in the first quarter. Renaissance Technologies LLC now owns 304,700 shares of the company’s stock worth $701,000 after purchasing an additional 54,600 shares during the last quarter. Finally, Mink Brook Asset Management LLC increased its position in MDxHealth by 64.9% in the fourth quarter. Mink Brook Asset Management LLC now owns 263,420 shares of the company’s stock worth $940,000 after purchasing an additional 103,686 shares during the last quarter.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.